Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients
Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure.
Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure
Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.
Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients
Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.
Sterile, temperature-controlled preservation reduces long-term mortality after heart transplant by 54%
An advanced preservation system from Paragonix, a Getinge company, was linked to dramatic reductions in both mortality and procedural complications.
Bayer's finerenone reduces risk of AFib, atrial flutter in all CKM syndrome patients
New data published in JACC represents another big win for Bayer's finerenone. The drug has previously been linked to cardiovascular benefits for patients with CKD and heart failure, but its potential across the full CKM spectrum remained a bit of a mystery.

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure.

tirzepatide injections Zepbound Eli Lilly

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

cannabis use disorder marijuana joint weed smoking

Consistent cannabis use linked to multiple cardiovascular risks for heart failure patients

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.

Paragonix SherpaPak Cardiac Transport System

Sterile, temperature-controlled preservation reduces long-term mortality after heart transplant by 54%

An advanced preservation system from Paragonix, a Getinge company, was linked to dramatic reductions in both mortality and procedural complications.

doctor with overweight patient who may be treated with TAVR or surgery

Bayer's finerenone reduces risk of AFib, atrial flutter in all CKM syndrome patients

New data published in JACC represents another big win for Bayer's finerenone. The drug has previously been linked to cardiovascular benefits for patients with CKD and heart failure, but its potential across the full CKM spectrum remained a bit of a mystery.

FDA announces new recall of Abbott heart pump accessories over significant safety risks

The mobile power units of certain HeartMate 3 and HeartMate II LVADs have been experiencing “sudden, unexpected performance issues” such as turning on, off or even restarting with no warning. These issues can potentially be fatal, according to an alert shared by the FDA.

WiSE CRT system EBR Systems leadless pacing

FDA approves leadless CRT device for heart failure

The WiSE CRT system is approximately the size of a single cooked grain of rice. It works with a patient’s existing implant to provide biventricular pacing.

FIRE1 Norm inferior vena cava (IVC) heart failure sensor

Implantable IVC sensor shows early potential to guide heart failure management

The goal is to measure changes in a patient’s IVC area and collapsibility, which can help anticipate when heart failure events might occur. This first-in-human study included data from the first 50 patients to receive the device.